| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Hoche Partners Pharma Holding S.A. | 84.38% | $2,867,018,231 | 2,077,549,443 | Hoche Partners Pharma Holding S.A. | 16 Apr 2025 | |||
| Flying Fish Ventures L.P. | 84.38% | $2,867,018,231 | 2,077,549,443 | Flying Fish Ventures, L.P. | 09 Apr 2025 | |||
| Saint Thomas Commercial S.A. | 84.38% | $2,867,018,231 | 2,077,549,443 | Saint Thomas Commercial S.A. | 09 Apr 2025 | |||
| Chemo Project, S.A. | 53% | $1,800,235,163 | 1,304,518,234 | Chemo Project, S.A. | 09 Apr 2025 | |||
| Becaril S.A. | 53% | $1,800,235,163 | 1,304,518,234 | Becaril S.A. | 09 Apr 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q1 | 0 | $0 | -$1,613,042 | 0 | |
| 2024 Q4 | 221,439 | $1,613,042 | +$1,242,140 | $2.34 | 5 |
| 2024 Q3 | 166,189 | $367,179 | -$32,329 | $2.2 | 5 |
| 2024 Q2 | 179,063 | $452,581 | +$209,627 | $2.51 | 7 |
| 2024 Q1 | 89,855 | $270,384 | -$634,351 | $2.9 | 9 |
| 2023 Q4 | 243,277 | $990,304 | +$226,732 | $4.07 | 11 |
| 2023 Q3 | 62,661 | $226,832 | -$33,859 | $3.62 | 8 |
| 2023 Q2 | 71,985 | $342,514 | -$629,823 | $3.97 | 9 |
| 2023 Q1 | 220,633 | $994,941 | -$1,900,378 | $4.51 | 6 |
| 2022 Q4 | 641,937 | $3,369,033 | -$2,182,064 | $5.25 | 7 |
| 2022 Q3 | 1,067,698 | $7,473,000 | -$5,257,642 | $7 | 8 |
| 2022 Q2 | 1,668,061 | $15,545,000 | -$1,097,988 | $9.32 | 10 |
| 2022 Q1 | 1,795,515 | $15,261,000 | -$1,244,081 | $8.5 | 9 |
| 2021 Q4 | 1,939,037 | $18,861,000 | -$318,530 | $9.75 | 12 |
| 2021 Q3 | 1,941,513 | $19,803,000 | +$19,803,000 | $10.2 | 15 |